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Abstract
Objective—Early intervention and prevention of psychosis remain a major challenge. Prediction 
would be greatly advanced with improved ability to identify individuals at true risk, which, at 
present, is moderate at best. The authors tested a modified strategy to improve prediction by 
selecting a more homogeneous high-risk sample (attenuated positive symptom criteria only, age 
range of mid-teens to early 20s) than is currently standard, combined with a systematic selection 
of neurodevelopmental deficits.
Method—A sample of 101 treatment-seeking adolescents (mean age, 15.9 years) at clinical high 
risk for psychosis were followed clinically for up to 5 years (mean follow-up time, 3.0 years, 
SD=1.6). Adolescents were included only if they exhibited one or more attenuated positive 
symptoms at moderate to severe, but not psychotic, severity levels. Cox regression was used to 
derive a risk index.
Results—The overall conversion rate to psychosis was 28.3%. The final predictor model, with a 
positive predictive validity of 81.8%, consisted of four variables: disorganized communication, 
suspiciousness, verbal memory deficits, and decline in social functioning during follow-up. 
Significant effects also suggest narrowing the risk age range to 15–22 years.
Conclusions—Clinical high risk criteria that emphasize disorganized communication and 
suspiciousness while also including compromised verbal memory and declining social functioning 
have the potential to improve predictive accuracy compared with attenuated positive symptoms 
used alone. On the resulting risk index (a weighted combination of the predictors), low scores 
were interpreted as signifying minimal risk, with little treatment necessary, high scores as 
suggesting aggressive intervention, and intermediate scores, although less informative, as 
supporting psychosocial treatment.
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Accurately identifying young people at risk for developing schizophrenia or related 
psychotic illnesses is the critical first step for developing effective prevention programs (1–
5). At present, preventive research typically focuses on individuals who have symptoms 
associated with the prodromal or pre-psychotic phases of illness (6–8). The primary goal is 
to preemptively intervene to slow, modify, or, optimally, stop progression to full illness (5). 
Moreover, establishing risk characteristics prior to onset of psychosis generates critically 
needed information about underlying mechanisms. Although several major rating systems 
are used extensively around the world (9–11), the Structured Interview for Prodromal 
Syndromes (SIPS), along with its companion rating scale, the Scale of Prodromal 
Symptoms, is most widely adopted throughout North America (12–14). At present, the 
North American rating system identifies three separate prodromal subgroups, defined by 
having 1) attenuated positive symptoms, considered an early, subtle form of the hallmark 
symptoms of psychosis; 2) positive symptoms at full psychotic intensity for brief, limited 
periods, referred to as “brief intermittent psychotic symptoms”; or 3) a trait/state 
combination of genetic risk or schizotypy accompanied by functional decline, labeled 
“genetic risk and deterioration.” Subgroups and criteria are similar to those specified in the 
Australian rating system (15), and in both, the three subgroups are combined into a single 
high-risk entity. However, the rates of conversion to psychosis among high-risk subjects so 
defined has remained moderate to low (2). One factor possibly contributing to the moderate 
predictive validity of the high-risk criteria is the implicit but untested assumption that the 
three subgroups are alike in risk factors and developmental pathways. Combining these three 
populations may mask or confound predictors and affect overall conversion rates (16) and, 
as a result, contribute to inconsistencies across sites. For example, patients with intermittent 
psychosis are by definition more seriously impaired and develop full-blown psychosis at a 
much higher rate than do individuals at genetic high risk (16). It is possible that a more 
accurate set of predictors may emerge by deconstructing the overall high-risk category back 
into its three major subgroups.
A second possible factor limiting predictive accuracy is reliance on attenuated positive 
symptoms as the primary criterion defining risk. Several studies (17–24) have reported a 
number of biobehavioral abnormalities (e.g., cognitive, functional, social) that appear, ad 
hoc, to improve prediction. However, none of these potential indicators has as yet been 
incorporated into the selection of high-risk subjects, a task that continues to depend on the 
SIPS or comparable symptom criteria despite the problematic conversion rates (2). One 
factor limiting inclusion of vulnerability indicators to the high-risk criteria is the marked 
inconsistency across studies in specific variables identified. The selection of domains for 
inclusion in prediction research has varied substantially from study to study, and even within 
similar domains, measures are often not comparable. Predictive accuracy might be improved 
by adding theory-driven deficits in domains other than positive symptoms, as we did in the 
present study, in which domains selected for prediction were derived from a theoretical 
neurodevelopmental model.
In this study, individuals in both the genetic-risk and the brief-intermittent-psychosis groups 
were excluded. Individuals were included only if they exhibited attenuated positive 
symptoms at clinically significant severity levels as defined by the SIPS. Duration of 
symptoms was treated as a dependent variable and was not limited to an onset or worsening 
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over the year prior to baseline, as specified by the criteria in standard use. In addition, 
selection of potential predictor variables was based primarily on the set of vulnerability 
indicators included in the neurodevelopmental model described by Cornblatt and colleagues 
at the Recognition and Prevention program in New York (1), and consistent with Weinberger 
(25), who proposed that a biologically based vulnerability resulting from genetic 
abnormalities is a major etiological component of psychosis. Four domains were proposed in 
the model to be major contributors to the underlying vulnerability: 1) cognitive deficits, 2) 
anxiety and depression, 3) social difficulties leading to increasing isolation, and 4) role 
functioning problems at school or work. These domains were originally selected because 
they had been broadly implicated in all phases of schizophrenia and appeared modifiable 
with early treatment and thus seemed optimal for early intervention (1).
We hypothesized that adding the selected vulnerability indicators to SIPS clinical criteria 
would improve predictive accuracy in a homogeneous subgroup of at-risk young people who 
were selected according to attenuated positive symptom severity and who were also within 
the optimum age window (ages 12–22, prior to typical onset age). A major goal of this study 
was to validate the selected vulnerability indicators for the specific at-risk population tested, 
with the long-term expectation that, if replicated, any one or more of these indicators might 
be added to the clinical high-risk criteria. The applicability of this approach to treatment is 
also illustrated. This involves further stratifying the initial at-risk sample according to the 
risk index derived here and then indicating how interventions might be developed to directly 
target the different stratified groups.
METHOD
Sample
The data reported here were collected as part of the Recognition and Prevention (RAP) 
program of the North Shore-Long Island Jewish Health System in New York, first funded by 
the National Institute of Mental Health in 2000. The RAP program is divided into two 
phases. Phase I participants, the focus of the present analyses, were recruited from 2000 to 
2006, with follow-up completed in 2010. In phase II, an independent replication sample was 
recruited from 2006 to 2012, and follow-up is expected to be completed in December 2016. 
Of the 192 treatment-seeking adolescents between 12 and 22 years old in RAP phase I, 101 
participants met clinical high-risk criteria, which require one or more moderate to severe 
attenuated positive symptoms (i.e., unusual thoughts, suspiciousness, grandiosity, perceptual 
abnormalities, disorganized communication) as rated on the SIPS (scores of 3–5 on a scale 
of 0–6) (12–14). Individuals with a score of 6 (severe and psychotic) on any positive 
symptom item are excluded. Symptom duration is measured as time from when an 
attenuated symptom first appears as moderate to severe but not at psychotic levels, based on 
all information available at baseline. Adolescents who have only attenuated negative 
symptoms or who meet criteria for brief intermittent psychosis or for psychotic disorder not 
otherwise specified are excluded from the present analyses, although they are included in the 
larger RAP study (see reference 1).
Healthy comparison subjects (N=68) were recruited through announcements in local 
newspapers and bulletin boards at the medical center. Comparison subjects had to be 12–22 
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years old and English speaking. Exclusion criteria were a schizophrenia spectrum diagnosis, 
a mood disorder with psychosis, a medical or neurological disorder affecting the brain, an 
estimated IQ <70, or a first-degree relative with an axis I psychotic disorder.
Patient referrals were made to the RAP program by affiliated outpatient and inpatient 
psychiatry departments, local mental health providers, school psychologists or counselors, or 
by self-referral.
All procedures were approved by the North Shore-Long Island Jewish Health System 
Institutional Review Board. Written informed consent (with assent from participants under 
age 18) was obtained from all participants.
Baseline Measures
Full details of the baseline neurocognitive and clinical assessment have been reported 
elsewhere (26–29). All participants were evaluated on a comprehensive battery of clinical, 
behavioral, functional, and neurocognitive measures, including the Schedule for Affective 
Disorders and Schizophrenia for School-Age Children–Epidemiologic Version (30) for axis 
I disorders and the SIPS for prodromal ratings. The Beck Depression Inventory (31) and the 
Beck Anxiety Scale (32) were used to measure self-reported symptoms of depression and 
anxiety. Social and role (academic or work) functioning was assessed using the Global 
Functioning: Social and Role scales (33). Neuropsychological measures assessed eight 
cognitive domains: processing speed, verbal memory, executive function, working memory, 
visuospatial processing, motor speed, sustained attention, and language (27–29).
Follow-Up Procedures
Follow-up interviews included SIPS ratings, the two global functioning scales, and the 
depression and anxiety self-reports. Conversion to psychosis was defined as the presence of 
a psychotic-level positive symptom (a score of 6 with a minimum duration of 1 week). Of 
the initial 101 subjects considered to be at clinical high risk, 92 (91%) had follow-up clinical 
ratings. The remaining nine subjects were lost to follow-up. The mean follow-up period 
(time to conversion to psychosis or to last follow-up in those who did not convert to 
psychosis) was 3.0 years (SD=1.6).
Statistical Analysis
All analyses were conducted in SPSS, version 16.0 (SPSS, Inc., Chicago). Comparisons of 
demographic and clinical characteristics were performed with analysis of variance for 
continuous variables and chi-square tests or Fisher’s exact test for categorical variables (two-
tailed, p<0.05). The cumulative incidence rates of transition to psychosis during the follow-
up period were estimated with Kaplan-Meier survival analysis (34).
A Cox proportional hazards model was used to evaluate the effects of potential predictors on 
outcome event (conversion) and time to each outcome event (time to transition). Predictor 
variables were generated by the RAP neurodevelopmental model (neurocognition, 
depression/anxiety, social and role deficits at baseline and follow-up). In addition, clinical 
characteristics were entered from the SIPS, and included total scores for the four scales 
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(positive, negative, disorganized, and general symptoms) and the durations of positive and 
negative symptoms. Demographic variables were also included (age, race, gender, ethnicity, 
and socioeconomic status), as well as comorbidity and medications at baseline and follow-
up (see Tables S1 and S2 in the data supplement that accompanies the online edition of this 
article).
Consistent with the analyses described by Cannon et al. (17) and Ruhrmann et al. (20), in the 
first stage of variable selection, all potential variables were computed individually in a 
univariable Cox regression analysis at a more liberal statistical threshold (p<0.25) (35). 
Variables that remained after the initial screening procedure were entered into domain-
specific regressions (p<0.10). A final multivariable model was built with the remaining 
variables using backward (stepwise, likelihood ratio method) inclusion (p<0.05). The −2 
log-likelihood ratio test was used to evaluate the overall significance of the predictive 
equation. The Wald chi-square statistic was used to test the significance of individual 
variables in the model. Model selection was guided by the Akaike information criterion 
modified for survival analyses (36). Bootstrap resampling with replacement (B=10,000 
bootstrap samples) was used to internally validate the final prediction model (see the online 
data supplement) (37).
After deriving a final Cox regression model, a weighted risk index was calculated by 
multiplying each coefficient estimate from the model by the corresponding observed value 
for each individual (i.e., b1X1+b2X2…+bkXk). The risk index was then converted into an 
estimated probability of converting to psychosis with the inverse logistic function. Model 
discrimination and diagnostic accuracy were determined with the C statistic (area under the 
curve). Model calibration was assessed with the Hosmer-Lemeshow (38) goodness-of-fit test 
(p≥0.10). Missing data were handled using expectation-maximization estimates (39). 
Overall, 4.9% of the data (392 of 8,004 values) were missing. No significant relationship 
was found between the patterns of missing data and outcome.
RESULTS
Table 1 presents baseline demographic and clinical data for the 92 participants at clinical 
high risk and the 68 healthy comparison subjects. There were no significant differences 
between groups in age, years of education, gender, or socioeconomic status. Healthy 
comparison subjects had higher estimated premorbid and current IQ, although the high-risk 
participants were well within the normal IQ range.
Clinical Characteristics
The total scores for all four SIPS scales are listed in Table 1. As expected, the healthy 
comparison subjects had either no symptoms or low symptoms levels (scores of 0–2), in 
contrast to the high-risk participants, who had clinically significant scores across the four 
scales. In terms of functioning, healthy comparison subjects exhibited good to above-
average social and role functioning (scores close to 9), whereas the clinical high-risk 
participants’ scores fell in the moderate to seriously impaired range (scores of 6.5 to 5.5). 
Compared with healthy comparison subjects, the high-risk participants had significantly 
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higher symptom scores across self-report and interview measures of depression, anxiety, and 
substance abuse.
Duration of Symptoms Prior to Study Entry
As shown in Table 1, the clinical high-risk participants exhibited both positive and negative 
symptoms considerably longer than the 1 year specified by the SIPS for attenuated positive 
symptoms (3.07 years for positive symptoms and 4.50 years for negative symptoms). No 
significant differences were found in conversion rates for participants with a symptom 
duration of 1 year or less (rate=24.1%, SE=0.095, N=28) compared with those with a longer 
prebaseline symptom duration (rate=20.0%, SE=0.065, N=57).
Medication
Of the participants who had already been treated for at least 4 weeks before study entry, 
about 30% received antidepressants, 20% anti-psychotics, 10% anxiolytics, and 4% mood 
stabilizers. At last follow-up, the percentages of high-risk participants receiving 
antipsychotics (39.1%; p<0.001), antidepressants (56.5%; p<0.001), and mood stabilizers 
(14.1%; p=0.04) were significantly higher than at baseline, indicating active 
pharmacological treatment throughout the follow-up period.
Neurocognition
The high-risk participants showed overall poorer neurocognitive performance than the 
healthy comparison subjects (Wilks’s lambda=0.77; F=5.32, df=8, 146, p<0.001). As shown 
in Table 2, the largest effect size differences were seen in verbal memory and processing 
speed.
Conversion Rates
Figure 1 presents the Kaplan-Meier estimate of the survival function for time to onset of 
psychosis in the clinical high-risk group. The mean time from baseline assessment to 
conversion to psychosis was 1.78 years (SD=1.40, median=1.46). The cumulative incidence 
rate of conversion was 5.6% for year 1 (SE=0.02, 95% CI=1.28–9.91), 11.9% for year 2 
(SE=0.04, 95% CI=4.84–18.96), 16.6% for year 3 (SE=0.04, 95% CI=8.17–25.0), and 
19.4% for year 4 (SE=0.05, 95% CI=9.60–29.20). There were no additional conversions 
during year 5. One additional conversion occurred during year 6, resulting in a cumulative 
rate of 28.3% (SE=0.10, 95% CI=9.68–46.92).
Prediction of Conversion
The final predictor model, adjusting for age, consisted of four variables: disorganized 
communication (any score above 2), suspiciousness (a rating of 5), verbal memory deficits 
(2 standard deviations below normal), and declining social functioning (as assessed with the 
Global Functioning: Social scale, from baseline to last follow-up). Surprisingly, Kaplan-
Meier analyses indicated that the youngest age group (ages 12–14, N=34) had a very low 
conversion rate of 3% (N=1). Therefore, the final multivariable model was adjusted for 
baseline age. Combining the four variables resulted in an area under the curve of 91.9% 
(95% CI=85.7–98.0, p<0.001), indicating an excellent discriminative ability, with a 
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sensitivity of 60.0%, a specificity of 97.4%, and a positive predictive value of 81.8%. (The 
negative predictive value was 92.6%; the positive likelihood ratio was 23.1, and the negative 
likelihood ratio was 0.41.) To determine whether active medication affected rate of 
conversion, medication at baseline and follow-up were added to the final prediction model. 
Treatment with antipsychotics, antidepressants, or mood stabilizers did not significantly 
predict conversion.
The estimates from the final Cox regression model were used to generate a risk index score 
and subsequent probability of conversion for each individual (Table 3). Figure 2 presents 
risk index scores derived from the regression weights plotted with the probability of 
conversion on an individual case level for those who converted to psychosis and those who 
did not. The figure illustrates a high accuracy level, with participants who did not convert to 
psychosis nearly all having low scores and most participants at the high end of the curve 
having converted to psychosis. Confusion in risk status is shown primarily for subjects 
falling in the middle, where index scores were not fully consistent with converter status. The 
Hosmer-Lemeshow statistic was 3.80 (p=0.88), suggesting a well-calibrated predictive 
model.
DISCUSSION
Our results indicate that a profile consisting of four variables—disorganized communication, 
suspiciousness, verbal memory, and declining social functioning—can significantly improve 
accuracy in predicting future psychosis in a selected, homogeneous risk population. In this 
study, based on current high-risk criteria alone (presence of one or more attenuated positive 
symptoms), the rate of conversion approached 30% with longitudinal follow-up, a rate that is 
consistent with the literature (2). However, when the expanded predictor profile was used 
instead of the standard symptom criteria, accuracy of prediction increased to 81.8%. This 
level of increased accuracy mirrors similar results previously reported (17–22; see the 
summary in reference 40). Nevertheless, there is in-sufficient consensus across studies as to 
which specific vulnerability indicator (e.g., cognitive, social) should be added to the clinical 
high-risk criteria. As a result, the clinical criteria have not changed substantively since they 
were originally introduced. Adding criteria to improve predictive accuracy would be the next 
step toward moving the field forward (41).
Neurodevelopmental Model as the Basis for Prediction
The present findings support the neurodevelopmental RAP model proposal that 
abnormalities other than attenuated positive symptoms have the potential to predict future 
psychosis. Of the four vulnerability indicators included in the model, verbal memory and 
social functioning were identified as critical predictors of psychosis. Contrary to 
expectation, however, depression/anxiety and role functioning did not predict future 
psychosis. Duration of symptoms prior to baseline, comorbidity, substance abuse, and 
medication also did not play a role in predicting psychosis. Similarly, none of the symptoms 
in the remaining three SIPS scales (negative, disorganized, and general) entered into the 
prediction model. Despite consistent evidence that cognitive deficits characterize all phases 
of psychosis, including the prodrome (42–44), few studies have included cognition in 
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predictor analyses. In one of the few exceptions, Riecher-Rössler et al. (19) found 
processing speed to be a major predictor of the onset of psychosis. In the present study, by 
contrast, verbal memory but not processing speed predicted the development of psychosis. 
Also contrary to expectation, a low conversion rate (3%) was observed among at-risk 
subjects ranging in age from 12 to 14 years, suggesting that including very young 
adolescents may be a factor in the inconsistent rates reported across studies. Overall, these 
findings highlight the problem of sample specificity, where predictors differ depending on 
the sample under study.
In contrast with the majority of potential vulnerability indicators, impaired functioning is 
one domain that has been associated with conversion to psychosis in a number of studies 
(17–19, 45–47). However, as pointed out by Nelson et al. (22), functioning is a complex 
construct in its own right and can incorporate many factors. Previous studies have typically 
relied on the Global Assessment of Functioning to generate predictor scores in the 
functioning domain. However, there is no way to parse these global scores into their social, 
clinical, and role components and thus no way to directly tailor intervention to the deficit 
most in need of remediation. In the present study, functioning was divided into two specific 
dimensions, social and role, with both domains assessed independently of clinical 
characteristics. These two independent aspects of overall functioning appear to have 
substantially different predictor potential. Social difficulties start at a relatively young age, 
and evidence of further decline over adolescence appears to be a solid predictor of illness 
(48). Role functioning appears to be more responsive to environmental conditions (e.g., 
change of school) than any of the other vulnerability indicators and may be primarily a state 
factor, most directly reflective of poor long-term functional outcome or disability (27, 28, 
48).
Personalized Prediction
The goal of prediction studies is to improve prevention by increasing the accuracy of 
positive identification and thus increasing the precision of intervention. According to the 
strategy proposed here, it may be most feasible to initially generate predictors of psychosis 
that are specific to narrower, well-defined populations than is currently the case, with 
subsequent replication across similar populations being essential. Validation would 
additionally depend on the effectiveness of interventions tailored to the specific deficits 
identified, also across similar homogeneous groups of subjects. Developing accurate 
prediction would then involve a gradual progression from a specialized, local predictor 
system to one that can be generalized to a more diverse population.
This study provides an example of how this might proceed. The first step is to improve 
prediction by calculating a risk index for a homogeneous high-risk group (e.g., use of a 
narrow definition and a restricted age range) from a set of theoretically derived potential 
predictors. The second step is to apply the resulting index to stratify risk within the overall 
group, consistent with the approach used by Ruhrmann et al. (20, 49, 50). The risk index 
score distribution generated in the present sample suggests that adolescents with the lowest 
scores can be considered to be at minimal risk and those with scores at the high end at very 
high risk, with the risk of the middle group somewhat uncertain. The third step is then to 
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personalize intervention to individuals, for example, by monitoring low-risk individuals, 
providing psychosocial treatment for those with intermediate risk, and providing more 
aggressive intervention, possibly involving medication, for those with the highest risk (i.e., 
those who exhibit serious verbal memory problems and social decline in addition to 
disorganized communication and high levels of suspiciousness).
PATIENT PERSPECTIVES
Conversion Cases
Case 1 (probability of conversion according to risk index score, 91.1%) is a 15-year-old 
male patient who presented with social and behavioral problems that had worsened in the 
year before he enrolled in the Recognition and Prevention (RAP) program. He reported 
that he had no friends and felt that no one liked him. In addition, he believed that others 
were talking negatively about him or intentionally trying to provoke him. He perseverated 
on these issues and occasionally reacted aggressively toward others based on his 
misperception of the situation. Conceptual disorganization was rated as moderately 
severe because of tangential speech and a tendency to go off track in the interview. In his 
academic performance, he was achieving grades in the range of 75–85 in special 
education classes, in which he had been enrolled since elementary school. His verbal 
memory skills were well below average. Over the follow-up period, his social functioning 
declined as his paranoid ideation increased to a delusional level, despite treatment with 
antipsychotic medication. He met full criteria for schizophrenia at the 1-year follow-up.
Case 2 (probability of conversion according to predictor risk index score, 79.8%) is an 
18-year-old female patient who presented with significant interpersonal problems, 
impulse control issues, suspiciousness, and intellectual limitations. She had a history of 
speech delay and attended special education programs throughout her academic career. 
Despite significant support, her grades declined over the high school years. Her verbal 
memory score was well below the mean at baseline. In addition, she had difficulties with 
peer relationships, which intensified in high school. She often engaged in verbal 
arguments and physical fights with peers that necessitated her changing schools. She was 
very jealous of others and felt that they were deceiving her or that they were not paying 
enough attention to her. She reacted impulsively to threats, and in addition to altercations 
with peers, she made two suicide attempts that resulted in hospitalizations. She received 
prescriptions for antipsychotic medication but was often nonadherent with treatment. 
Although there was no evidence of conceptual disorganization at baseline, her thought 
process became more idiosyncratic and disorganized over the follow-up period. She 
additionally developed grandiose delusions and evidenced a further decline in her 
functioning. She was given a diagnosis of schizophrenia a year and half after baseline.
Non-Conversion Cases
Case 3 (probability of conversion according to predictor risk index score, 14.4%) is a 16-
year-old male patient who reported a long history of panic attacks and intense anxiety 
when around people that led him not to attend school for 2 years and to avoid people in 
general. His anxiety around people had both an avoidant component (related to fears 
about embarrassing himself or being rejected) and a paranoid component (related to fears 
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that people are bad and dangerous), although it seemed that the paranoid aspect was more 
pervasive. Despite these problems, he had the capacity and desire to relate to people. He 
had become depressed, possibly in response to his anxiety and isolation, but also because 
of family stressors. He also reported unusual experiences, such as a vision from 
childhood that held meaning for him, the idea that objects moved mysteriously in his 
room, and the sense that there was a dark force behind him. There was no evidence of 
conceptual disorganization or problems with verbal memory or cognition. He was treated 
with an antidepressant and cognitive-behavioral therapy. He was eventually placed in a 
more supportive school environment and was passing all his classes. At the 3-year 
follow-up, he remained slightly wary of others, but not suspicious, and had made a few 
friends. He no longer reported unusual experiences at last contact.
Case 4 (probability of conversion according to predictor risk index score, 17.7%) is a 15-
year-old female patient with a 2-year history of depression, anxiety, and obsessive-
compulsive symptoms. She reported depressed mood, irritability, loss of interest, and 
decreased concentration. She reported panic attacks with agoraphobia and feelings of 
depersonalization. She had ongoing worries, mainly about illness and death, and she 
washed her hands 10 times a day. Formerly an A/B student, her grades had slipped to C’s 
before she enrolled in the RAP program, although she had no notable cognitive 
impairments. She also had the unusual idea that parts of her body didn’t seem real and 
that she had a speech impediment (which she did not). She reported feeling that other 
people were laughing at her, and at times in the past she had believed that her mother 
might be trying to poison her food. She attended therapy and took antidepressant 
medication intermittently over 3 years of follow-up. When she stopped taking 
antidepressants, her obsessive-compulsive symptoms and paranoia returned, although her 
symptoms never reached a psychotic level.
Translating a statistical index into clinical terms is complex. The preliminary findings from 
this study suggest that for our adolescent sample, individuals are at particularly high risk if 
they display clinically significant evidence of disorganized communication, very high levels 
of suspiciousness, verbal memory problems that would be more severe than those displayed 
by at least 95% of the subjects tested, and a substantial decline in social interactions (in the 
case of the Global Functioning scales used in this study, a decline of one point or more). 
Conceptual disorganization, as measured by the SIPS, is weighted most heavily in the 
predictor algorithm. Considered the precursor to formal thought disorder, conceptual 
disorganization is characterized by speech observed to be perseverative and tangential and 
by a lack of ability to organize one’s thoughts, ranging from vague or confusing speech to 
not giving direct answers to questions. Severe levels of suspiciousness on the SIPS (a score 
of 5), with the second highest algorithm weight, are exemplified by beliefs, without any 
objective evidence, that others are intentionally provoking or intending to harm the 
individual. Preoccupation with such beliefs sometimes leads to confrontations and verbal 
altercations with others. The verbal memory deficit is associated with extremely impaired 
performance on the California Verbal Learning Test, a measure of list learning. In the 
present sample, difficulty encoding auditory verbal information appears to reflect a 
developmental cognitive abnormality that severely disrupts academic achievement in most of 
the adolescents at the high end of the risk spectrum. Lastly, the majority of cases with high 
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risk index scores had problems with social functioning. While this is a common problem in 
treatment-seeking adolescents, the participants considered at particularly high risk had few 
friends at study entry and continued to withdraw from relationships over the follow-up 
period, with a trajectory of decline in social interactions.
It should be emphasized that application of the algorithm for screening in community and 
clinical settings should be done with considerable caution at this point, since predictors 
weighted on specific high-risk samples do not apply to other populations. For example, 
outreach to general school populations that recruit individuals who are not treatment seeking 
may generate a wholly different sample for which the algorithm used here would not be 
valid.
Limitations
It may be too early in the course of prodromal research to generate predictor profiles that 
will generalize across many different sites or populations. Developing site-specific predictor 
profiles that may have direct clinical application, as proposed here, has a number of 
limitations, the need for cross-validation being a primary one. In the short term, it will be 
necessary to determine whether the risk index used in this study will generalize to similar 
homogeneous clinical high-risk populations recruited independently either at the same or at 
different sites. Applicability to samples selected on the basis of the more heterogeneous 
standard criteria is a longer-term goal. The personalized prediction reported is intended to be 
an example of how a model such as the one used here might be applied in a clinical setting 
to identify individuals most and least in need of aggressive intervention based on sample-
specific deficit profiles. This strategy will need to be evaluated in terms of the success of 
interventions structured to accommodate the deficits specifically identified. A limitation of 
the model illustrated here is that while those at very high and very low risk are clearly 
identified, there is more ambiguity among subjects in the middle range; these individuals 
may require additional screening, most likely involving biological measures, such as 
neuroimaging or genetics, for more conclusive accuracy of prediction (51, 52).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Kaplan-Meier Estimate of the Cumulative Survival in the Group at Clinical High Risk for 
Psychosis (N=92)
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FIGURE 2. Risk Index and Predicted Probability of Conversion to Psychosisa
aThe risk index on the x-axis was generated by the regression model.
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